47 / 74 · 0:52 · Original AXON film
CagriSema
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
A defined combination
CagriSema refers to a research combination of cagrilintide and semaglutide. Evidence for that combination comes from studying a defined product in a defined trial. [1]
REDEFINE 1 | phase 3a
REDEFINE 1 enrolled 3,417 adults with obesity or overweight and a related complication, without diabetes. The randomized trial included combination, single-drug, and placebo groups. [1]
68-week weight outcome
At 68 weeks, the combination reduced body weight more than placebo. Gastrointestinal adverse events were frequent, so tolerability belongs alongside the weight result. [1]
Formulation stays attached to evidence
The published findings do not establish that any two ingredients mixed together behave identically. Formulation, manufacturing, study population, and follow-up all shape what the evidence supports. [1]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- Garvey et al. (2025): Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity →REDEFINE 1 design, 3417 participants, 68-week weight result, and gastrointestinal adverse events.
